Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings.
amorphous solid dispersions
congruent
drug loading
drug release
phase behavior
polymer release
surfactant
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
13
04
2021
revised:
04
05
2021
accepted:
10
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
To reduce the dosage size of amorphous solid dispersion (ASD)-based formulations, it is of interest to devise formulation strategies that allow increased drug loading (DL) without compromising dissolution performance. The aim of this study was to explore how surfactant addition impacts drug release as a function of drug loading from a ternary ASD, using felodipine as a model poorly soluble compound. The addition of 5% TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate, a surfactant) to felodipine-polyvinylpyrrolidone/vinyl acetate ASDs was found to facilitate rapid and congruent (i.e., simultaneous) release of drug and polymer at higher DLs relative to binary ASDs (drug and polymer only). For binary ASDs, good release was observed for DLs up to <20% DL; this increased to 35% DL with surfactant. Microstructure evolution in ASD films following exposure to 100% relative humidity was studied using atomic force microscopy coupled with nanoscale infrared imaging. The formation of discrete, spherical drug-rich domains in the presence of surfactant appeared to be linked to systems showing congruent and rapid release of drug and polymer. In contrast, a contiguous drug-rich phase was formed for systems without surfactant at higher DLs. This study supports the addition of surfactant to ASD formulations as a strategy to increase DL without compromising release. Furthermore, insights into the potential role of surfactant in altering ASD release mechanisms are provided.
Identifiants
pubmed: 34067666
pii: pharmaceutics13050735
doi: 10.3390/pharmaceutics13050735
pmc: PMC8156319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bristol-Myers Squibb
ID : N/A
Références
Int J Pharm. 2002 Jan 14;231(2):131-44
pubmed: 11755266
Int J Pharm. 2018 Apr 5;540(1-2):106-119
pubmed: 29425762
J Pharm Sci. 2018 Jan;107(1):317-326
pubmed: 29107047
Int J Pharm. 2017 Aug 30;529(1-2):654-666
pubmed: 28705623
Pharmaceutics. 2018 Apr 24;10(2):
pubmed: 29695136
Eur J Pharm Sci. 2019 Aug 1;136:104955
pubmed: 31199980
Eur J Pharm Sci. 2020 Dec 1;155:105514
pubmed: 32810579
Eur J Pharm Biopharm. 2008 May;69(1):158-66
pubmed: 18164929
Mol Pharm. 2018 Feb 5;15(2):571-584
pubmed: 29313693
Mol Pharm. 2016 May 2;13(5):1467-81
pubmed: 27019407
Eur J Pharm Biopharm. 2008 Oct;70(2):493-9
pubmed: 18577451
Mol Pharm. 2018 Apr 2;15(4):1700-1713
pubmed: 29513538
Mol Pharm. 2021 May 3;18(5):2066-2081
pubmed: 33784104
Mol Pharm. 2015 Feb 2;12(2):533-41
pubmed: 25569461
Mol Pharm. 2008 Nov-Dec;5(6):994-1002
pubmed: 19434852
Int J Pharm. 2014 Jan 30;461(1-2):251-7
pubmed: 24333451
Mol Pharm. 2020 Apr 6;17(4):1261-1275
pubmed: 32134677
Mol Pharm. 2020 Oct 5;17(10):4004-4017
pubmed: 32931293
Mol Pharm. 2020 Apr 6;17(4):1352-1362
pubmed: 32097023
Drug Dev Ind Pharm. 2018 Apr;44(4):677-686
pubmed: 29164955
Int J Nanomedicine. 2012;7:5757-68
pubmed: 23166440
Pharm Res. 2003 Oct;20(10):1647-54
pubmed: 14620521
Int J Pharm. 2018 Jan 15;535(1-2):379-392
pubmed: 29128423
J Pharm Sci. 2017 Aug;106(8):1998-2008
pubmed: 28431965
Mol Pharm. 2019 Dec 2;16(12):5054-5067
pubmed: 31689113
Drug Dev Ind Pharm. 2016;42(3):429-45
pubmed: 26355819
Mol Pharm. 2017 Jul 3;14(7):2437-2449
pubmed: 28591516
J Pharm Sci. 2013 Jan;102(1):34-42
pubmed: 23147500
Mol Pharm. 2019 Apr 1;16(4):1751-1765
pubmed: 30811205
Pharmaceutics. 2021 Jan 14;13(1):
pubmed: 33466598
J Control Release. 2018 Dec 28;292:172-182
pubmed: 30408553
J Control Release. 2019 Mar 28;298:68-82
pubmed: 30731151
Pharm Res. 2017 Dec;34(12):2842-2861
pubmed: 28956218
J Pharm Pharm Sci. 2005 Jul 08;8(2):147-65
pubmed: 16124926
Mol Pharm. 2019 Dec 2;16(12):4836-4851
pubmed: 31682129
Mol Pharm. 2019 Mar 4;16(3):1327-1339
pubmed: 30669846
Int J Pharm. 2007 Aug 1;340(1-2):76-83
pubmed: 17478064
Mol Pharm. 2018 Sep 4;15(9):3796-3812
pubmed: 30020788
J Pharm Sci. 2019 Sep;108(9):2917-2925
pubmed: 30980857
Pharm Res. 2000 Apr;17(4):397-404
pubmed: 10870982
J Pharm Sci. 2019 Jan;108(1):50-57
pubmed: 30439459